TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06280105
Drug: Cadonilimab+regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: cadonilimab: 6mg/kg iv D1 Q2W; regorafenib: 80mg QD oral; Eligible patients will receive cadonilimab combined with regorafenib, until disease progression or intolerable toxicity or death or withdrawal of informed consent, whichever occurred first
Study: NCT05860530
Drug: The test olaparib tablet (T)
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The test olaparib tablet (Qilu Pharmaceutical Co., Ltd., Jinan, China) 300mg, every 12 hours
Study: NCT05860530
Drug: The reference olaparib tablet (R)
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The reference olaparib tablet (Lynparza®; AstraZeneca PLC, Cambridge, England, UK) 300mg, every 12 hours
Study: NCT05137145
Drug: Linaclotide
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The observation group 1 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine, and the observation group 2 was given Linaclotide in 1 day combined with 4L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. observation group 3 was given Linaclotide in 3 day combined with 3L of Compound Polyethylene Glycol Electrolyte Powder to clear the intestine. Intestinal cleanliness and the incidence of adverse reactions of patients in each group were compared.
Study: NCT05137145
Drug: Compound Polyethylene Glycol Electrolyte Powder
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group was given Compound Polyethylene Glycol Electrolyte Powder to clear the intestines,
Study: NCT06253429
Drug: Captopril 25Mg Tab
Normalized name: CAPTOPRIL 25MG TAB
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral angiotensin-converting enzyme inhibitors
Study: NCT04802785
Drug: Citicoline
Normalized name: Citicoline
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline 500 mg (Vitaae®) per os
Study: NCT04802785
Drug: Cytochrome C6
Normalized name: HYDROGENATED C6-20 POLYOLEFIN (100 CST)
DrugBank: Cytochrome C (DB18543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytochrome10 mg per os
Study: NCT04802785
Drug: Sodium Chloride Oral Product
Normalized name: sodium chloride Oral Product
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Chloride (NaCl) 2.6 g. per os
Study: NCT04802785
Drug: Potassium Chloride Oral Product
Normalized name: potassium chloride Oral Product
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium Chloride 1.5 g per os
Study: NCT04802785
Drug: Sodium Citrate Oral Product
Normalized name: sodium citrate Oral Product
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Citrate 2.90 g per os
Study: NCT04802785
Drug: Domperidone Oral Product
Normalized name: domperidone Oral Product
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 1 tablet per os
Study: NCT04802785
Drug: Simethicone
Normalized name: Simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-4 capsules per os
Study: NCT04802785
Drug: Magnesium hydroxide
Normalized name: Magnesium Hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: magnesium hydroxide 30 mg per os
Study: NCT03899597
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention group (ARTCON) will receive the standard assignment for the elective caesarean section, but at least one hour before surgery oxytocin exposure will be performed with cardiotocographic (CTG) monitoring and obstetrical supervision.
Study: NCT04763408
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral capsules.
Study: NCT04763408
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablets.
Study: NCT04784780
Drug: Elobixibat 10mg
Normalized name: elobixibat
DrugBank: Elobixibat (DB12486)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Patients with chronic constipation are administered Elobixibat 10mg for 12 weeks
Study: NCT00295412
Drug: quetiapine (drug)
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01053065
Drug: Atorvastatin - Cholestyramine - Sitosterol
Normalized name: sitosterols
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04846478
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, taken by mouth, once a day
Study: NCT04846478
Drug: Tazemetostat
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: orally as a tablet twice daily.
Study: NCT05001412
Drug: Camrelizumab; apatinib; carboplatin; etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 cycle chemotherapy (carboplatin and etoposide), and then 2 cycle chemotherapy (carboplatin and etoposide) combine with Camrelizumab and apatinib, finally maintenance therapy with Camrelizumab and apatinib
Study: NCT05001555
Drug: Dexketoprofen
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of dexketoprofen 25 mg, orally, every 8 hours, for 7 days.
Study: NCT06012695
Drug: NBM-BMX Capsule
Normalized name: BMX-001 free base
DrugBank: BMX-001 free base (DB17516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each capsule contains 100 mg of the active ingredient.
Study: NCT06012695
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMZ will be administered orally at a 75 mg/m2 dose daily during concomitant therapy. In the maintenance period, days 1-5 of each cycle will be administered 150-200 mg/m2.
Study: NCT05628272
Drug: application of granulocyte stimulating factor
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: application of granulocyte stimulating factor
Study: NCT04776876
Drug: Telotristat Ethyl
Normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT05961384
Drug: baxdrostat
Normalized name: Baxdrostat
DrugBank: Baxdrostat (DB19090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a blood pressure lowering drug, oral dose
Study: NCT05130021
Drug: MAX-40279-01
Normalized name: bimatoprost 0.01 MG
DrugBank: MAX-40279 (DB15191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAX-40279-01 50mg/70mg
Study: NCT05130021
Drug: regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: regorafenib
Study: NCT06582771
Drug: Sotorasib
Normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sotorasib 960 mg (8 pills) daily
Study: NCT06362642
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antifungal treatment that is a potent inhibitor of CYP3A4.
Study: NCT04181463
Drug: Isopropyl Alcohol
Normalized name: Isopropyl Alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given via nasal inhalation
Study: NCT05556967
Drug: Immulina
Normalized name: Immucin
DrugBank: Immucin (DB17403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immulina is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
Study: NCT06258304
Drug: GIGA-564
Normalized name: Hippoglossus gigas flesh
DrugBank: Atlantic halibut (DB15549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous infusion
Study: NCT04920292
Drug: Oxfendazole
Normalized name: Oxfendazole
DrugBank: Oxfendazole (DB11446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxfendazole is a benzimidazole anthelminthic drug.
Study: NCT04903509
Drug: BI 1820237
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1820237
Study: NCT00001049
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05919823
Drug: Xanomeline and Trospium Chloride Capsules
Normalized name: trospium chloride / xanomeline Pill
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-35 unless the subject is experiencing adverse events from the xanomeline 100 mg/ trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/ trospium 20 mg depending on clinical response and tolerability.
Study: NCT00001049
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05259540
Drug: compound kushen injection combined with pabolizumab
Normalized name: BENZOIN COMPOUND
DrugBank: Benzoin (DB14020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: compound kushen injection 20ml/day and pabolizumab 200mg/21 days, both drugs are given intravenously
Study: NCT05782127
Drug: Onureg + Venetoclax
Normalized name: Onureg
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combination of Onureg and Venetoclax
Study: NCT06535737
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib (Cabometyx) 60, 40 and 20 mg
Study: NCT05358639
Drug: Olaparib tablet
Normalized name: Olaparib Tablets
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib tablet will be administered alone for 14 days at a starting dose of 200 mg twice daily. Subsequently olaparib will be administered continuously over 28 days at a fixed dose and the dose of navitoclax will be escalated.
Study: NCT05358639
Drug: Navitoclax
Normalized name: navitoclax
DrugBank: Navitoclax (DB12340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For navitoclax, a lead-in of 7 days at 150 mg PO will be used prior to dose escalation. The DLT period for dose levels above DL 3 will include the 14-day olaparib alone lead-in, the 7 days combination with navitoclax at 150 mg and the first 28 day cycle of the combination of olaparib and navitoclax cycle at the full dose level dosing (49 days).
Study: NCT00000738
Drug: Nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000738
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01637571
Drug: Dexilant
Normalized name: Dexilant
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mg of Dexilant QD for 12 weeks
Study: NCT01637571
Drug: Dexilant Placebo
Normalized name: Dexilant
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mg of Dexilant placebo QD for 12 weeks
Study: NCT06393426
Drug: Chinese Herb
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
DrugBank: Ginger (DB10344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine
Study: NCT04087876
Drug: derazantinib
Normalized name: Derazantinib
DrugBank: Derazantinib (DB14889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: derazantinib will be administered orally
Study: NCT06050512
Drug: Mezigdomide
Normalized name: Mezigdomide
DrugBank: Mezigdomide (DB17584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezigdomide (MEZI), a novel oral CELMoD® agent with enhanced tumoricidal and immune-stimulatory effects compared to immunomodulatory drugs (IMiDs®), induces maximal degradation of Ikaros and Aiolos, leading to increased apoptosis in myeloma cells.
Study: NCT06050512
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixazomib, a second-generation proteasome inhibitor, is used primarily in the treatment of multiple myeloma. This activity outlines the mechanism of action, indications, and contraindications for ixazomib as a valuable agent for treating multiple myeloma.
Study: NCT06050512
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Corticosteroids, such as dexamethasone and prednisone, are an important part of the treatment of multiple myeloma. They can be used alone or combined with other drugs as a part of treatment. Corticosteroids are also used to help decrease the nausea and vomiting that chemo might cause.
Study: NCT05028088
Drug: sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: This study is a prospective, double-blind, low-intervention, non-randomized controlled clinical trial involving 99 patients with American Society of Anesthesiologists Ⅰ-Ⅲ, body mass index 18.5-24.9 kg/m2, who will undergo laparoscopic radical resection of liver cancer under general anesthesia in the Wuhan Union Hospital. Ultrasonography will be applied to monitor the change rate of diaphragm thickness at different time after extubation to evaluate the recovery rate of muscle relaxant, which indirectly reflects the dose-effect relationship of SUG antagonizing against rocuronium in patients with different liver Child-Pugh grades preoperatively.
Study: NCT00394537
Drug: Labetalol 10mg iv
DrugBank: Labetalol (DB00598)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04920994
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 ml 0.25% bupivacaine will be injected after the negative aspiration test.
Study: NCT06663293
Drug: midazolam, ketamine, propofol
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sedation was done with IV midazolam 0.025 to 0.1 mg/kg, IV ketamine 0.25 to 0.5 mg/kg, and IV propofol (1%) 0.25 to 0.5 mg/kg
Study: NCT06663293
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sedation maintenance was done by propofol 0.5 to 1 mg/kg/h
Study: NCT05785767
Drug: fianlimab
Normalized name: Fianlimab
DrugBank: Fianlimab (DB18858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every three weeks (Q3W) as intravenous (IV) co-infusion
Study: NCT05785767
Drug: cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Q3W as IV co-infusion
Study: NCT06684535
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive 29 ml bupivacaine 0.25% + 1 ml dexmedetomidine 0.5 μg/kg.
Study: NCT06684535
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 29 ml bupivacaine 0.25% + 1 ml saline.
Study: NCT06695585
Drug: Lidocaine 2% without vessel constrictor
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: different volumes of intravesical 2% lidocaine without epinephrine, all patients will be receiving bladder botox but this will not be compared
Study: NCT06685796
Drug: BEBT-209 capsules
Normalized name: bebtelovimab
DrugBank: Bebtelovimab (DB16755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEBT-209 Capsules, dosage: 150mg, frequency and duration of administration: administered on days 1, 2, 8, and 9 of each cycle, with a 21-day cycle. On days 1 and 8, take orally once before dinner or twice (before breakfast and before dinner), and on days 2 and 9, take orally once before breakfast.
Study: NCT06685796
Drug: Carboplatin injection
Normalized name: Carboplatin Injection
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin injection, dosage: AUC 2 × (creatinine clearance rate + 25), frequency and duration of administration: administered on days 1 and 8 or days 2 and 9 of each cycle, with a 21-day cycle.
Study: NCT06685796
Drug: Gemcitabine hydrochloride for injection
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine hydrochloride for injection, dosage: 1000mg/m², frequency and duration of administration: administered on days 1 and 8 or days 2 and 9 of each cycle, with a 21-day cycle.
Study: NCT05103735
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: awake neurosurgery under propofol-remifentanil sedation
Study: NCT06023368
Drug: EMLA Cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cream applied around the port prior to access
Study: NCT05918302
Drug: 177Lu-edotreotide
Normalized name: edotreotride
DrugBank: Edotreotide (DB17969)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of 7.5 ± 0.7 Giga becquerel (GBq) 177Lu-edotreotide
Study: NCT05918302
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg orally once daily (QD)
Study: NCT05080543
Drug: Albumin 20% and terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation the effect of adding 20% HSA and terlipressin on microvascular ﬂow index (MFI), flow heterogeneity index, total vessel density (TVD), and perfused vessel density (PVD) in comparison to the standard care in patient with septic shock.
Study: NCT06081348
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral capsule (25mg, 50mg, 100mg, 200mg)
Study: NCT04885712
Drug: Metformin≥1000mg
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects take the investigational products once a day for 24 weeks.
Study: NCT04885712
Drug: Pioglitazone 15mg
Normalized name: METFORMIN 500MG/PIOGLITAZONE 15MG TAB
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects take the investigational products once a day for 24 weeks.
Study: NCT04885712
Drug: Pioglitazone 30 mg
Normalized name: pioglitazone 30 MG
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects take the investigational products once a day for 24 weeks.
Study: NCT04885712
Drug: Pioglitazone 15mg Placebo
Normalized name: pioglitazone 15 MG
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects take the investigational products once a day for 24 weeks.
Study: NCT04885712
Drug: Pioglitazone 30mg Placebo
Normalized name: pioglitazone 30 MG
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects take the investigational products once a day for 24 weeks.
Study: NCT04885712
Drug: Dapagliflozin 10mg
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects take the investigational products once a day for 24 weeks.
Study: NCT05574400
Drug: Dextrose Water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose 5% in water
Study: NCT05540600
Drug: Digoxin 0.25 mg
Normalized name: digoxin 0.25 MG
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will have the dose of one tablet of 0.25mg per day
Study: NCT05540600
Drug: Bisoprolol
Normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will have the dose of bisoprolol 2.5 mg or 5 mg twice a day based on the arterial pressure at randomization
Study: NCT06074185
Drug: Ipratropium Bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study intervention involves implementing a treatment bundle that includes inhaled ipratropium bromide and dexamethasone.
Study: NCT04814433
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA-approved usage for intravenous tranexamic acid (TXA) is for heavy menstrual bleeding and short-term prevention in patients with hemophilia.~Total dose of 500 mg (20 mL) total will be given.
Study: NCT04814433
Drug: Aminocaproic acid
Normalized name: Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA notes that aminocaproic acid is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. Aminocaproic acid inhibits both the action of plasminogen activators and to a lesser degree, plasmin activity. The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.~Total of 1000 mg total will be given.
Study: NCT04546620
Drug: R-CHOP + acalabrutinib
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B patients will receive R-CHOP in combination with acalabrutinib.
Study: NCT05100017
Drug: Methocarbamol
Normalized name: Methocarbamol
DrugBank: Methocarbamol (DB00423)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive oral Methocarbamol 750mg every six hours as needed for pain post ureteroscopy in addition to the standard postoperative pain regimen.
Study: NCT05100017
Drug: Oxybutynin
Normalized name: Oxybutynin
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive oral Oxybutynin XL 10mg daily for pain post ureteroscopy in addition to the standard postoperative pain regimen.
Study: NCT04744129
Drug: NN414
Normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To investigate the role of NN414 on cerebral hemodynamic in migraine patients
Study: NCT04744129
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To investigate the role of NN414 compared with saline cerebral hemodynamic in migraine patients.